Rhizen Pharmaceuticals SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
26
About the Report
About the Report
Summary
Rhizen Pharmaceuticals SA (Rhizen Pharma), a subsidiary of Alembic Pharmaceuticals Ltd is a biopharmaceutical company that discovers and develops small molecule drugs. The company's research products includes c-Met inhibitors, selective P13K inhibitors, CRAC channel inhibitors and GPR 119 agonist. It conducts research in the therapeutic areas of oncology, immune inflammation and metabolic disorders such as diabetes and obesity. Rhizen Pharma's products find application in the treatment of diseases such as solid tumors, B cell lymphomas, hematological malignancies, asthma, diabetes and chronic obstructive pulmonary disease, among others. It collaborates with other pharmaceutical companies. Rhizen is headquartered in La Chaux-de-Fonds, Switzerland.
Rhizen Pharmaceuticals SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Rhizen Pharmaceuticals SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 10
Licensing Agreements 12
Novartis Enters into Licensing Agreement with Rhizen Pharma 12
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 13
Rhizen Pharmaceuticals SA-Key Competitors 14
Rhizen Pharmaceuticals SA-Key Employees 15
Rhizen Pharmaceuticals SA-Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Product News 17
06/14/2017: TG Therapeutics Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma 17
06/08/2017: TG Therapeutics Announces Clinical Data Presentation of TGR-1202 at the Upcoming 14th International Conference on Malignant Lymphoma 18
05/19/2017: TG Therapeutics Announces Data on TG R-1202 at the Upcoming 14th International Conference on Malignant Lymphoma 19
Clinical Trials 20
Jun 13, 2017: TG Therapeutics Recaps Schedule of Clinical Data Presentations of TGR-1202 at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress 20
Jun 05, 2017: TG Therapeutics Announces Follow-Up Data from the Chemo-Free Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 53rd Annual Meeting of the American Society of Clinical Oncology 22
Apr 20, 2017: TG Therapeutics Announces Clinical Data Presentations on TGR-1202 at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology 24
Jan 04, 2017: TG Therapeutics Announces Investigator Initiated Trial at the University of Nebraska Medical Center to Study TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26
List of Figure
List of Figures
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List of Table
List of Tables
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Key Facts 2
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Rhizen Pharmaceuticals SA, Deals By Therapy Area, 2012 to YTD 2018 8
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 10
Novartis Enters into Licensing Agreement with Rhizen Pharma 12
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 13
Rhizen Pharmaceuticals SA, Key Competitors 14
Rhizen Pharmaceuticals SA, Key Employees 15
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.